Open access · US-GOV
via ClinicalTrials.gov Clinical trial
PRODIGE 102 - FFCD 2201 - SAFE-ESO Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
Authors not listed
University Hospital, Clermont-Ferrand · 2025
Abstract
The goal of this clinical trial is to assess the percentage of patients alive at 6 months in elderly patients, not eligible to an platinum-based chemotherapy, but who can received the Tislelizumab treatment alone as first-line treatment for an advanced esophageal squamous-cell carcinoma (ESCC).
Tislelizumab is a monoclonal antibody administred by intravenous infusion
This study aims to anwer too at the questions:
* the Safety of the drug
* Overall survival (OS) at 6 months according the diagnostic of PD-L1 expression (PD-L1 is a protein present on the surface of immune cells)
* Overall response rate (ORR) according to imagery criteria
* Progression-free survival (PFS) at 3 and 6 months according to imagery criteria and depending on PDL1 expression
* Patients' health-related quality of life
* OS and PFS according to geriatric parameters
* Prognostic value of immune biomarkers
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-13 MST
Cite this
APA
Anonymous. (2025). PRODIGE 102 - FFCD 2201 - SAFE-ESO Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma. <em>University Hospital, Clermont-Ferrand</em>. https://clinicaltrials.gov/study/NCT07205731
Vancouver
Anonymous. PRODIGE 102 - FFCD 2201 - SAFE-ESO Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma. University Hospital, Clermont-Ferrand. 2025.
BibTeX
@misc{anon2025PRODIG,
title = {PRODIGE 102 - FFCD 2201 - SAFE-ESO Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma},
author = {Anonymous},
journal = {University Hospital, Clermont-Ferrand},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Tianjin Medical University Cancer Institute and Hospital 2025
Open access · US-GOV
Concurrent Chemoradiation Plus Iparomlimab Consolidation Therapy for Older Patients With Inoperable Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-arm Phase II Clinical Study
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2023
Open access · US-GOV
Nimotuzumab Concurrent With Chemoradiotherapy for Elderly or Malnourished Patients With Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Study
The First Affiliated Hospital of Xiamen University 2021
Open access · US-GOV
A Phase II Study of Envafolimab as First-line Treatment of Aged Patients With High PD-L1 Expression Stage in Advanced Non-small-cell Lung Cancer(NSCLC)
VA Office of Research and Development 2015
Open access · US-GOV
CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly
Three Gorges Hospital of Chongqing University 2021
Open access · US-GOV
An Observational Study on the Safety and Efficacy of Immunotherapy Combined With Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
Jonsson Comprehensive Cancer Center 2026
Open access · US-GOV